Lanean...
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
WHAT IS KNOWN AND OBJECTIVE: In recent years, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) including once‐weekly (QW) formulations have been incorporated into type 2 diabetes (T2D) clinical guidelines, making it essential that pharmacists and healthcare professionals (HCPs) have a clear und...
Gorde:
| Argitaratua izan da: | J Clin Pharm Ther |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540535/ https://ncbi.nlm.nih.gov/pubmed/32910487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcpt.13225 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|